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AbstrACt
Objective To assess the 24- month cost- effectiveness of 
total knee replacement (TKR) plus non- surgical treatment 
compared with non- surgical treatment with the option of 
later TKR if needed.
Methods 100 adults with moderate- to- severe knee 
osteoarthritis found eligible for TKR by an orthopaedic 
surgeon in secondary care were randomised to TKR plus 
12 weeks of supervised non- surgical treatment (exercise, 
education, diet, insoles and pain medication) or to 
supervised non- surgical treatment alone. Including quality- 
adjusted life years (QALYs) data from baseline, 3, 6, 12 
and 24 months, effectiveness was measured as change at 
24 months. Healthcare costs and transfer payments were 
derived from national registries. Incremental healthcare 
costs, and incremental cost- effectiveness ratios (ICERs) 
were calculated. A probabilistic sensitivity analysis was 
conducted and the probability of cost- effectiveness was 
estimated at the 22 665 Euros/QALY threshold defined by 
the National Institute for Health and Care Excellence.
results TKR plus non- surgical treatment was more 
expensive (mean of 23 076 vs 14 514 Euros) but also more 
effective than non- surgical treatment (mean 24- month 
improvement in QALY of 0.195 vs 0.056). While cost- 
effective in the unadjusted scenario (ICER of 18 497 
Euros/QALY), TKR plus non- surgical treatment was not 
cost- effective compared with non- surgical treatment with 
the option of later TKR if needed in the adjusted (age, sex 
and baseline values), base- case scenario (ICER of 32 611 
Euros/QALY) with a probability of cost- effectiveness of 
23.2%. Including deaths, TKR plus non- surgical treatment 
was still not cost- effective (ICERs of 46 277 to 64 208 
Euros/QALY).
Conclusions From a 24- month perspective, TKR plus 
non- surgical treatment does not appear to be cost- 
effective compared with non- surgical treatment with the 
option of later TKR if needed in patients with moderate- 
to- severe knee osteoarthritis and moderate intensity pain 
in secondary care in Denmark. Results were sensitive to 
changes, highlighting the need for further confirmatory 
research also assessing the long- term cost- effectiveness 
of TKR.
trial registration number  ClinicalTrials. gov 
(NCT01410409).
IntrOduCtIOn
Knee osteoarthritis (OA) is one of the leading 
contributors to the global burden of disease1 
with considerable pain and functional limita-
tions for the individual.2 The disease has 
been estimated to affect 250 million people 
worldwide,3 with total European costs esti-
mated to be 817 billion Euros per year.4 Over 
the last 20 years, the prevalence of knee OA 
has increased substantially5 and is expected 
to continue to increase1 and amplify the soci-
etal burden.
strengths and limitations of this study
 ► This is the first economic evaluation of total knee 
replacement (TKR) that is based on a randomised 
trial of surgical and non- surgical treatment thereby 
providing highly comparable treatment groups as-
sessed and treated in a standardised and controlled 
setup.
 ► Cost data were retrieved from the Danish health 
registries which contain detailed, high- quality in-
formation on health sector costs, social costs and 
prescription medication on individual patients, and 
effectiveness data were systematically and rigor-
ously collected in the randomised trial.
 ► The 24- month time horizon and the selected pop-
ulation included limit conclusions on the long- term 
cost- effectiveness of total knee replacement and the 
generalisability to other populations.
 ► Since nearly one out of three from the non- surgical 
group had TKR surgery during the 24 months, it is 
likely that the true additional effect and cost of TKR 
in addition to non- surgical treatment have been un-
derestimated in the study.
copyright.
 on January 20, 2020 at A
alborg U
niversity Library. P
rotected by
http://bm
jopen.bm
j.com
/
B
M
J O
pen: first published as 10.1136/bm
jopen-2019-033495 on 15 January 2020. D
ow
nloaded from
 
2 Skou ST, et al. BMJ Open 2020;10:e033495. doi:10.1136/bmjopen-2019-033495
Open access 
In patients with end- stage knee OA, total knee 
replacement (TKR) is considered an effective6 and 
cost- effective7 treatment. However, approximately 20% 
continue to have chronic pain after otherwise successful 
surgery8 and, in addition, the procedure is associated 
with a risk of serious adverse events.9 Furthermore, 
clinical guidelines reflecting high- quality evidence 
from recent decades highlight non- surgical treatments 
as an effective and less costly treatment for patients 
with knee OA.10 As the number of TKR procedures 
performed each year has increased dramatically since 
the 1970s,11 with around 600 000 annual procedures 
in the USA alone,12 evidence of the effectiveness and 
cost- effectiveness of TKR in comparison to non- surgical 
treatments is warranted.7
In 2015, a randomised trial assessing the effectiveness of 
TKR plus non- surgical treatment as compared with non- 
surgical treatment alone was published.13 Being the first 
of its kind, the study provided high- quality evidence on 
the effects of TKR and, at the same time, offered a unique 
opportunity to study the cost- effectiveness of TKR in two 
highly comparable treatment groups, thereby making 
an important contribution to previous non- randomised 
analyses of TKR cost- effectiveness.7 14
The purpose of the current study was to report the 24 
months cost- effectiveness of TKR plus non- surgical treat-
ment as compared with non- surgical treatment with the 
option of later TKR if needed using quality- adjusted life 
years (QALYs) data from the randomised trial and the 
unique Danish health registries which contain detailed 
information on health sector costs, social costs and 
prescription medication on the trial participants. We 
hypothesised that TKR plus non- surgical treatment would 
be a more cost- effective procedure compared with non- 
surgical treatment with the option of later TKR if needed 
at 24 months due to greater improvements in quality of 
life counterbalancing the expected additional cost related 
to the surgery.
MethOds
study design
This was a preplanned baseline to 24 months cost- 
utility analysis from a parallel group assessor- blinded 
randomised trial (1:1 ratio) that conforms to the 
Consolidated Health Economic Evaluation Reporting 
Standards statement for reporting health economic 
evaluations.15 Costs were collected from a health system 
perspective, with QALYs used as the outcome measure. 
Individual- level data were obtained from the clinical 
trial and linked with data from national registries for use 
in the analyses.
A brief presentation of the trial methods is provided 
below. Full details about the process for recruitment, 
criteria for eligibility, the randomisation procedure, allo-
cation concealment and detailed description of the inter-
ventions have been published previously.16
Participants
One hundred patients diagnosed with symptomatic 
and moderate- to- severe radiographic knee OA consid-
ered eligible for TKR by the orthopaedic surgeon were 
included in the study. The study had three major exclu-
sion criteria: (1) mean pain the previous week above 
60 mm on a 100 mm Visual Analogue Scale, (2) previous 
knee replacement on the same side and (3) need for 
bilateral simultaneous TKR.
setting and time horizon
Patients were recruited between September 2011 and 
December 2013 from one of two specialised, public outpa-
tient clinics at Aalborg University Hospital, Denmark 
(Frederikshavn and Farsø), and all patients provided 
informed written consent before being enrolled. To 
have identical time periods for the whole population, we 
compared resource use and costs 1 year before randomis-
ation (pre- period) to resource use and costs 2 years after 
randomisation for each individual patient.
randomisation procedure and allocation concealment
The randomisation schedule was generated a priori in 
permuted blocks of eight, stratified by site and the allo-
cation numbers were concealed in sealed, opaque enve-
lopes prepared by an independent staff member. One 
research assistant at each of the two sites had access to 
the envelopes, opening them only after informed consent 
and baseline outcomes had been obtained.
Comparators
Patients were randomly assigned (1:1) to (1) undergo 
TKR plus 12 weeks of supervised non- surgical treatment 
or (2) receive only the 12 weeks of supervised non- surgical 
treatment.
Total knee replacement
A total cemented prosthesis with patellar resurfacing 
(NexGen, CR- Flex, fixed bearing or LPS- Flex, fixed 
bearing, Zimmer, Warsaw, Indiana, USA) was inserted 
by high- volume orthopaedic specialists (a surgeon 
performing +100 TKRs/year) using the surgical methods 
recommended by the manufacturer.17 Surgery was 
performed by the surgeon in charge of the assessment at 
the time of recruitment.
Supervised non-surgical treatment
The 12- week individualised, non- surgical treatment 
programme included exercise, patient education and 
insoles, with dietary advice and/or pain medication 
prescribed, if indicated. The treatments were delivered 
by physiotherapists and dietitians at Aalborg University 
Hospital, Denmark.
Exercise
The NEuroMuscular EXercise training programme 
(NEMEX), previously found feasible in patients with 
moderate- to- severe knee OA awaiting joint replacement,18 
was administered in 60 min group- based sessions twice 
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weekly supervised by a physiotherapist. To increase long- 
term adherence, after 12 weeks of exercise, the patients 
undertook a transition period of 8 weeks where the exer-
cise programme was increasingly performed at home.
Patient education
Patient education was delivered as two 60 min group- based 
educational sessions which actively engaged the patients 
in their treatment. The sessions focused on disease char-
acteristics, advice about treatment and self- help. Sessions 
were held in groups of up to 16 patients and were facili-
tated by the project physiotherapist.
Dietary advice
Patients with a body mass index ≥25 at baseline had four 
individual 1- hour consultations with a dietitian with the 
overall aim of reducing body weight by at least 5%.19 The 
programme was based on motivational interviewing.20
Insoles
Patients received individually fitted full- length Formthotics 
Original Dual Medium (perforated) insoles with medial 
arch support (Foot Science International, Christchurch, 
New Zealand). A 4° lateral wedge was added to the insoles 
if patients had a knee- lateral- to- foot position (the knee 
moves over, or lateral, to the fifth toe in three or more of 
five trials).21
Pain medication
Paracetamol 1 g four times daily, ibuprofen 400 mg three 
times daily and pantoprazole 20 mg daily were prescribed 
by the orthopaedic surgeon if indicated. Prescriptions 
were reassessed every 3 weeks and the patients were 
instructed to contact the study team if they were uncer-
tain about the need for continued pain medication.
Booster sessions
After the 12- week non- surgical programme and the 8- week 
transition period and until the 12- month follow- up, a 
physiotherapist phoned the patients monthly to support 
exercise adherence. Patients consulting the dietitian were 
telephoned twice by the dietitian to encourage dietary 
adherence.
Patient and public involvement
While no patients were involved in this cost- effectiveness 
analysis, the specific content of the non- surgical treat-
ment was guided by feedback from patients to ensure 
feasibility and acceptance.
Measurement of resource use and costs
Information on resource use and costs, including health-
care costs and public transfer income for each patient, 
was retrieved from Danish national registries up until the 
24- month follow- up. In Denmark, the Danish Civil Regis-
tration System assigns every citizen a personal identifi-
cation number (central personal registration number), 
which allows for the linking of information between 
national registries at the individual level. This enables 
identification of the patients in the trial and calculations 
of costs associated with these individuals. Healthcare costs 
comprised expenses associated with inpatient services, 
outpatient visits, primary care services and prescription 
medication. Inpatient services were assessed as both 
including and excluding TKR surgeries during the 
study period. Data on inpatient and outpatient services 
are available from the National Patient Registry (NPR), 
which contains information on all kinds of patient 
contacts including diagnoses and diagnostic and treat-
ment procedures. Linking data on resource use from 
NPR with the Danish Case Mix System (Diagnosis- Related 
Groups) enabled estimation of associated costs. Primary 
care included visits to the general practitioner, medical 
specialist, physiotherapist, chiropractor, laboratory work 
and others. Resources related to utilisation of the primary 
care services were derived from the Danish National 
Health Insurance Service Register. Costs were estimated 
for all prescription medication; pain medication (The 
Anatomical Therapeutic Chemical (ATC)- codes N02A, 
N02B and M01A) and non- pain medication (ie, anything 
else besides pain medication), respectively. Medication 
costs were calculated by multiplying the retail price with 
the prescribed quantity, available from the Danish Medi-
cines Agency.
Non- protocol- driven resources, for example, costs of 
recruitment, were not included. As both groups received 
the same supervised non- surgical treatment (as described 
above), this cost was not included for either group. The 
cost of the non- surgical treatment was estimated to be 
between 560 Euros (actual cost of the non- surgical treat-
ment in the trial) to 1646 Euros (estimated cost of the 
non- surgical treatment in private practice in Denmark) 
per person.
To increase the international applicability of the study, 
costs were adjusted to 2015- equivalent price levels using 
the consumer price index and converted to Euros (1 
Euro=7.45 Danish Kroner); 1 Euro corresponded to 1.13 
US dollars at the 2017 average exchange rate.
Public transfer income was calculated as the number 
of weeks a person was receiving sick leave pay, disability 
pension, early retirement and unemployment benefits 
(including activated persons). About half of the partici-
pants were older than 64 years (56%), and retired (age 
pension). This information was available from national 
registries from Statistics Denmark.
Measurement of effectiveness
A generic measure of health in terms of QALYs gained 
was used as the effectiveness measure of effects up until 
the 24- month follow- up. This is a composite measure that 
considers both the quantity and quality of life of an indi-
vidual. The maximum achievable health utility is 1 and 
hence, a QALY value of 1 reflects 1 year of full health, 
whereas a QALY value of 0 reflects death. Health- related 
quality of life (HRQoL; health utility) was measured using 
the three- level version of the EuroQol Group 5- Dimension 
Self- Report Questionnaire (EQ- 5D), including the score 
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on the descriptive index (ranging from −0.59 to 1.00) 
and the score on the Visual Analogue Scale (ranging 
from 0 to 100),22 at baseline, at 3 months, 6 months, 12 
months and at the 24 months follow- up. The baseline to 
12 months EQ- 5D data were previously published in the 
primary randomisedcontrolled trial report,13 but has not 
previously been used for cost- effectiveness analyses. The 
EQ- 5D- 3L has five digits measuring mobility, self- care, 
usual activities, pain discomfort and anxiety/depres-
sion. The descriptive index is based on a Danish ‘time 
trade- off’ value set,23 which is a method used to evaluate 
the relative amount of time patients would be willing to 
sacrifice to avoid a certain poor health state. The patients 
completed the EQ- 5D at baseline and all follow- up visits 
at the Department of Occupational Therapy and Physio-
therapy, Aalborg University Hospital, Denmark.
Analytical methods
Missing data
Missing data were handled by using multiple imputa-
tion, which enables individuals with incomplete data to 
be included in the analysis. The underlying assumption 
when using multiple imputation is that data are missing 
at random, that is, the probability of missing values is 
not dependent on unobserved data. Missing data were 
imputed using multiple imputation in SAS, and the 
assumption of data missing at random was also tested 
and confirmed in SAS. Missing utility values occurred at 
3, 6, 12 and 24 months, and thus, utilities were imputed 
at these time points using utilities from available time 
points.
Costs in the pre-period, year 1 and year 2
The costs of the two groups were compared by using arith-
metic means for each period. The statistical significance 
of the difference between groups was assessed using the 
bootstrapped t- test.
Cost-effectiveness analyses
Regression analyses were used to estimate incremental 
costs and QALYs and data were analysed in accordance 
with intention- to- treat principle. Costs in the regression 
analyses only included healthcare costs. Because costs 
are normally right- skewed and QALYs left- skewed, a 
gamma distribution was assumed in the regression anal-
yses. Both regression analyses were adjusted for covariates 
in the base- case analysis, that is, the cost regression was 
adjusted for age, sex and baseline costs and the QALY 
regression was adjusted for age, sex and baseline QALY. 
Two additional scenarios were also considered: one not 
taking covariates into account, that is, without adjustment 
(Scenario 1), and the other not considering either covari-
ates or missing values/imputations (Scenario 2).
QALY gains or losses were calculated as the area under 
the curve, that is, taking changes in utility over time into 
account.
Costs and effects were discounted by 3%.
Subanalysis
A subanalysis, including deaths during the study period, 
was conducted for each scenario (Base- case scenario, 
Scenario 1 and Scenario 2).
Sensitivity analyses
A probabilistic sensitivity analysis was carried out for 
each scenario in the primary analysis and the subanalysis, 
respectively. The probabilistic sensitivity analysis takes 
into account all parameter uncertainty at once. Incre-
mental costs and QALYs were used to simulate 10 000 
random draws resulting in a scatterplot reflecting the 
probability of cost- effectiveness. In Denmark, no officially 
set willingness- to- pay threshold exists. Instead, we used a 
threshold of 22 665 Euros/QALY or lower corresponding 
to the decision rule defined by the National Institute for 
Health and Care Excellence (NICE) (£ 20 000).24
A cost- effectiveness acceptability curve illustrating 
the cost- effectiveness at different thresholds and a cost- 
effectiveness plane showing the uncertainty around 
the incrementalcost- effectiveness ratios (ICER) were 
produced (both excluding deaths).
All analyses were performed using SAS 9.1.3 (SAS Insti-
tute, North Carolina, USA) and the significance level was 
set to 0.05.
results
Patient characteristics
The baseline characteristics of the two groups of patients 
and patient flow are presented in table 1 and figure 1, 
respectively. Below 8% (n=117) of patients assessed for 
eligibility were excluded due to pain intensity above 
60 mm out of 100 mm.
Out of the 100 patients randomised, 24 months 
follow- up data were available for 47/50 (94%) in the non- 
surgical group and 43/50 (86%) in the TKR plus non- 
surgical group. Administrative data yielded that 16 out of 
50 patients (32%) from the non- surgical group had a TKR 
before the 24 months follow- up: 13 patients from baseline 
to 12 months and 3 patients between 12 and 24 months. 
Mean duration (range) from initiating the non- surgical 
treatment to the TKR was 8.7 (2.6 to 21.5) months. One 
of the 50 patients (2%) in the TKR plus non- surgical 
group decided not to undergo TKR anyway. One patient 
in the TKR plus non- surgical group had three revision 
surgeries ending up with the prosthesis being removed 
and the knee fused following a deep infection. Due to 
severe knee stiffness during the rehabilitation period 
after TKR, three patients in the TKR plus non- surgical 
group and one patient in the non- surgical group who 
had TKR later required manipulation of the knee under 
anaesthesia. The mean follow- up time was 24.0 and 24.3 
months in the TKR plus non- surgical group and the non- 
surgical group, respectively.
Table 2 shows healthcare costs and public transfer 
income given as weeks in the pre- period, year 1 (12 
months) and year 2 (24 months), respectively. The groups 
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Table 1 Baseline characteristics in the randomised controlled trial of patients eligible for total knee replacement (TKR)
Baseline characteristics
TKR-+non- surgical group
(n=50)
Non- surgical group
(n=50)
Women, n (%) 32 (64) 30 (60)
Age (years), mean (SD) 65.8 (8.7) 67.0 (8.7)
Body mass index, mean (SD) 32.3 (6.2) 32.0 (5.8)
Bilateral knee pain, n (%) 18 (36) 17 (34)
Radiographic knee OA severity (Kellgren- Lawrence), n (%)
  Grade 1 0 (0) 0 (0)
  Grade 2 7 (14) 5 (10)
  Grade 3 21 (42) 21 (42)
  Grade 4 22 (44) 24 (48)
KOOS
  Pain 48.6 (17.5) 49.5 (13.1)
  Symptoms 54.0 (15.0) 58.3 (15.2)
  ADL 55.0 (17.0) 53.5 (14.2)
  Sport/rec 18.0 (14.7) 16.7 (15.1)
  QOL 32.3 (15.3) 32.7 (13.3)
  KOOS4 47.4 (13.4) 48.5 (11.4)
Timed Up and Go test, seconds 9.4 (2.4) 8.6 (2.1)
20- metre walk test, seconds 13.4 (3.7) 12.2 (2.6)
Used pain medication in the last week, yes n (%) 33 (67) 29 (58)
Radiographic severity: Radiographic knee osteoarthritis severity on the Kellgren- Lawrence scale; KOOS4: The mean score of four out of five of 
the Knee injury and Osteoarthritis Outcome Score subscales covering Pain, Symptoms, Function in daily living (ADL), Sport/Rec: Function in 
sport and recreation. and Quality of life (QOL), with scores ranging from 0 to 100 (worst to best scale).
OA, osteoarthritis.
had similar healthcare costs during the year prior to 
randomisation (2695 vs 2644 Euros). At 12 months after 
randomisation, healthcare costs in the TKR plus non- 
surgical group were more than double those of the non- 
surgical group (16 343 vs 7028 Euros), mostly due to the 
surgical procedure. Although not statistically significant, 
the costs in the TKR plus non- surgical group were lower 
at the 24 months follow- up (6733 vs 7486 Euros) because 
some patients in the non- surgical group underwent TKR. 
No significant between- group differences were found in 
weeks of incurring public transfer income.
The non- surgical group experienced a gain in health 
utilities of 0.056 from baseline to 24 months while the 
TKR plus non- surgical group experienced a gain of 0.195, 
with the largest increases in health utilities in both groups 
from baseline to 3 months (see table 3 for utility values at 
the different time points).
Incremental costs and QALYs for each scenario are 
presented in table 4. In all scenarios, TKR plus non- 
surgical treatment was more expensive, but also more 
effective in terms of QALY gain. ICERs and the probability 
of cost- effectiveness at the willingness- to- pay threshold for 
each scenario are also presented in table 4. In the Base- 
case (adjusted) scenario, TKR plus non- surgical treatment 
costed 32 611 Euros per QALY gained, which is above the 
threshold for willingness- to- pay defined by NICE (22 665 
Euros/QALY). However, in the unadjusted Scenario 1 
and unadjusted and without imputation of missing values 
(Scenario 2) the ICERs were below the threshold (19 917 
Euros/QALY and 18 497 Euros/QALY, respectively). The 
probability of cost- effectiveness of TKR plus non- surgical 
treatment was only 23.2% in the (adjusted) Base- case 
scenario, but increased to 58.3% and 61.9% in Scenarios 
1 and 2, respectively.
Cost- effectiveness acceptability curve showing the prob-
ability of TKR plus non- surgical treatment being cost- 
effective at different thresholds is presented in figure 2. 
The probability of cost- effectiveness was below 60% up 
until a threshold of approximately 40 000 Euros/QALY. 
To reach a probability of cost- effectiveness greater than 
90%, a threshold of minimum 60 000 Euros/QALY was 
needed.
Cost- effectiveness plane illustrating the uncertainty 
around the ICER is presented in online supplementary 
appendix figure 1.
subanalysis including deaths
Three persons died in the TKR plus non- surgical treat-
ment group and one person in the non- surgical treatment 
only group. Including deaths in the analysis decreased 
the QALY gained in both groups. The non- surgical 
group experienced a gain in health utilities of 0.040 from 
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Figure 1 Flow of patients in the randomised controlled trial of patients eligible for total knee replacement. K- L score, Kellgren- 
Lawrence score; OA,osteoarthritis; TKR,total knee replacement; VAS, Visual Analogue Scale.
baseline to 24 months while the TKR plus non- surgical 
group experienced a gain of 0.136, with the largest 
increases in health utilities in both groups from baseline 
to 3 months (see online supplementary appendix table 1 
for utility values at the different time points).
Including deaths in the regression analysis changed the 
estimates of incremental costs and QALYs (online supple-
mentary appendix table 2). TKR plus non- surgical treat-
ment was still more expensive and more effective for all 
scenarios but in all three scenarios the ICER exceeded the 
NICE threshold. In the Base- case scenario, the ICER was 
more than twice as high as the threshold for willingness- 
to- pay defined by NICE (22 665 Euros/QALY), and 
the probability of cost- effectiveness was only 7.8%. In 
Scenarios 1 and 2 the probability of cost- effectiveness was 
12.4% and 13.8%, respectively.
dIsCussIOn
TKR plus non- surgical treatment appear to be more 
expensive, but also more effective than non- surgical treat-
ment after 24 months in patients with knee OA eligible for 
TKR and moderate intensity pain. The cost- utility analysis 
suggested that TKR plus non- surgical treatment was not 
cost- effective compared with non- surgical treatment with 
the option of later TKR if needed from a 24- month health 
system perspective in secondary care in Denmark when 
adjusting for covariates and imputing missing values. 
Results were sensitive to changes, as the treatment was 
cost- effective in the unadjusted scenario, highlighting the 
need for further research with 5 to 10- year time horizons.
Given the extensive burden of knee OA,3 4 there is 
considerable societal demand for evidence on cost- 
effective evidence- based treatments.25 The current study 
provides the first direct comparison of two different 
treatment strategies in terms of cost- effectiveness after 24 
months for patients with moderate- to- severe symptomatic 
and radiographic knee OA. The cost- utility analysis was 
conducted alongside a randomised trial, which demon-
strated that TKR plus non- surgical treatment compared 
with non- surgical treatment was twice as effective in 
terms of pain relief and functional improvements after 
12 and 24 months.13 26 Therefore, we hypothesised that 
TKR would be a cost- effective procedure after 24 months 
due to higher improvements in quality of life counterbal-
ancing the expected additional cost related to the proce-
dure. However, in contrast to our hypothesis, TKR plus 
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non- surgical treatment was not found to be cost- effective 
compared with non- surgical treatment with the option 
of later TKR if needed from a 24 months perspective in 
secondary care in Denmark. The cost per QALY gained 
exceeded the threshold defined by NICE by approxi-
mately 10 000 Euros.24 However, without adjustment for 
covariates and imputation of missing values the cost per 
QALY was just cost- effective according to the threshold 
(ICER of 18 497 Euros/QALY).
Our results from the Base- case scenario contrast with 
findings in a recent systematic review.27 The review 
included four studies examining the cost- effectiveness 
of TKR compared with non- surgical procedures and 
all four concluded that TKR was a cost- effective option. 
However, as opposed to our study, none of the previous 
studies were based on a randomised trial and the content 
of the non- surgical treatment was neither as compre-
hensive nor aligned with evidence- based recommenda-
tions as the non- surgical treatment in our study. Two of 
the previous studies used a Markov model to assess the 
long- term and lifetime cost- effectiveness of TKR.28 29 The 
remaining two were cohort- based studies examining short- 
term cost- effectiveness of TKR.30 31 A recent cohort- based 
cost- effectiveness analysis, not included in the systematic 
review, concluded that TKR was not cost- effective at a 
group level over 8 years, while it would be cost- effective if 
it was restricted to patients with more severe symptoms.14 
In contrast, we did not find that TKR was cost- effective 
in addition to non- surgical treatment after 24 months in 
patients with moderate intensity pain. Our study provides 
the first cost- effectiveness analysis of TKR in addition to 
recommended non- surgical treatment using two compa-
rable treatment groups, thereby providing an important 
addition to the above- mentioned non- randomised studies.
One could argue that extending the time horizon might 
have led to a different conclusion. If the positive effect 
of the surgery persists beyond the 24 months, TKR plus 
non- surgical treatment might eventually end up being a 
cost- effective option. Though the mean utility fluctuates 
slightly over time in both groups, there seems to be an 
overall improvement in the TKR plus non- surgical group 
as compared with non- surgical treatment only. Assuming 
that this between- group difference is at least maintained 
and a potential increased cost in the non- surgical group 
due to future TKR surgery, this could improve the cost- 
effectiveness ratios in favour of TKR plus non- surgical 
treatment. However, as indicated by a previous report,32 
improvements in symptoms might decline from 1 to 5 
years after TKR, questioning the assumptions under-
lining a potential long- term cost- effectiveness of TKR. 
In the TKR plus non- surgical group, three people died 
during the period, while only one person died in the non- 
surgical group. When including the deaths in the analysis, 
TKR plus non- surgical treatment was still more effective 
than non- surgical treatment, though not as effective as in 
the primary analysis. This is because death corresponds 
to a QALY value of 0, thereby attenuating the effect of 
the surgery.
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Table 4 Primary analysis excluding deaths. Incremental cost- effectiveness ratios (ICERs) and probability of cost- effectiveness 
of TKR plus non- surgical treatment versus non- surgical treatment alone for each scenario
Analysis
Incremental 
cost
95% CI
Incremental 
effect
95% CI
ICER
Probability of cost- 
effectiveness at 22 665 
Euros
Euros QALY
Euros/
QALY %
Base- case 6070 1857 to 10 283 0.186 0.078 to 0.294 32 611 23.2
Scenario 1 4640 −200 to 9480 0.233 0.088 to 0.378 19 917 58.3
Scenario 2 4481 −668 to 9629 0.242 0.095 to 0.390 18 497 61.9
Base- case=adjusted for age, sex and baseline value; Scenario 1=unadjusted; Scenario 2=unadjusted and without imputation of missing 
values.
QALY, quality- adjusted life year; TKR, total knee replacement.
Figure 2 Cost- effectiveness acceptability curve illustrating the probability of TKR plus non- surgical treatment being cost- 
effective at different thresholds (excluding deaths). QALY,quality- adjusted life years; TKR, total knee replacement.
strengths and limitations
All treatments, in particular surgical treatment, are associ-
ated with placebo effects.33 As our study did not include a 
sham surgery control group, we were not able to evaluate 
the proportion of the 24 months treatment effects attrib-
utable to contextual factors.34 Neither did we include 
a group receiving TKR without the non- surgical treat-
ment, leaving us without the possibility of evaluating the 
additional effect and cost of the non- surgical treatment. 
As 32% from the non- surgical group had TKR surgery 
during the 24 months, it is likely that the true additional 
effect and cost of TKR have been underestimated in the 
study. Furthermore, as one of the exclusion criteria was 
mean pain the previous week above 60 mm on a 100 mm 
Visual Analogue Scale, our results might not be gener-
alisable to patients with more severe pain at baseline. 
However, 42% of the patients reported pain higher than 
60 mm when asked about worst pain during the previous 
24 hours and the mean pain intensity in our trial of 49 on 
a 0 to 100 worst to best scale is comparable to a range of 
previous clinical studies evaluating pain severity prior to 
TKR.35–37 Additionally, the effects from non- surgical treat-
ments, such as exercise, does not seem to be associated 
with pain severity at baseline,38 suggesting that the non- 
surgical treatment might be as effective in patients with 
more severe pain. The short time horizon and the 
different findings in the analysis without adjustment 
for covariates and imputation of missing values and the 
subanalysis including deaths emphasise the susceptibility 
of the results and highlight the need for further analyses 
in the field including follow- ups at 5 to 10 years. The 
study strengths include the highly comparable treatment 
groups as a result of the randomisation and the use of 
data from the unique Danish registries, which comprise 
data deemed to be of high quality. Linkage between 
these registries and the Danish Civil Registration system 
allowed for retrieving data on an individual level, which is 
a unique feature of this study.
COnClusIOns
From a 24 months perspective in secondary care in 
Denmark, TKR plus non- surgical treatment does not 
appear to be cost- effective compared with non- surgical 
treatment with the option of later TKR if needed in 
patients with moderate- to- severe osteoarthritis and 
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moderate intensity pain, eligible for TKR. However, as 
TKR plus non- surgical treatment was just cost- effective 
when not adjusting for covariates and not imputing 
missing values, further confirmatory studies with longer 
follow- up are needed.
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